Enriqueta Vallejo-Yagüe1, Julia N Pfund1, Theresa Burkard1, Carole Clair2, Raphael Micheroli3, Burkhard Möller4, Axel Finckh5, Andrea M Burden1. 1. Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. 2. Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland. 3. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 4. Department of Rheumatology and Immunology, Inselspital, University Hospital of Bern, Bern, Switzerland. 5. Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland.
Abstract
OBJECTIVE: To compare the likelihood of achieving remission between men and women with rheumatoid arthritis (RA) after starting their first biologic or targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD). METHODS: This cohort study in the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry included RA patients starting their first b/tsDMARD (1997-31/04/2018). The odds of achieving remission at ≤12-months, defined by disease activity score 28-joints (DAS28) <2.6, were compared between men and women. Secondary analyses were adjusted for age and seropositivity, and we investigated potential mediators or factors that could explain the main findings. RESULTS: The study included 2839 (76.3%) women and 883 (23.7%) men with RA. Compared to women, men were older at diagnosis and b/tsDMARD start, but had shorter time from diagnosis to b/tsDMARD (3.4 versus 5.0 years, p<0.001), and they had lower DAS28 at b/tsDMARD start. Compared to women, men had 21% increased odds of achieving DAS28-remission, with odds ratio (OR) 1.21, 95% confidence interval (CI) 1.02-1.42. Adjusting for age and seropositivity yielded similar findings (adjusted OR 1.24, 95%CI 1.05-1.46). Analyses of potential mediators suggested that the observed effect may be explained by the shorter disease duration and lower DAS28 at treatment initiation in men versus women. CONCLUSION: Men started b/tsDMARD earlier than women, particularly regarding disease duration and disease activity (DAS28), and had higher odds of reaching remission. This highlights the importance of early initiation of second line treatments, and suggests to target an earlier stage of disease in women to match the benefits observed in men.
OBJECTIVE: To compare the likelihood of achieving remission between men and women with rheumatoid arthritis (RA) after starting their first biologic or targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD). METHODS: This cohort study in the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry included RA patients starting their first b/tsDMARD (1997-31/04/2018). The odds of achieving remission at ≤12-months, defined by disease activity score 28-joints (DAS28) <2.6, were compared between men and women. Secondary analyses were adjusted for age and seropositivity, and we investigated potential mediators or factors that could explain the main findings. RESULTS: The study included 2839 (76.3%) women and 883 (23.7%) men with RA. Compared to women, men were older at diagnosis and b/tsDMARD start, but had shorter time from diagnosis to b/tsDMARD (3.4 versus 5.0 years, p<0.001), and they had lower DAS28 at b/tsDMARD start. Compared to women, men had 21% increased odds of achieving DAS28-remission, with odds ratio (OR) 1.21, 95% confidence interval (CI) 1.02-1.42. Adjusting for age and seropositivity yielded similar findings (adjusted OR 1.24, 95%CI 1.05-1.46). Analyses of potential mediators suggested that the observed effect may be explained by the shorter disease duration and lower DAS28 at treatment initiation in men versus women. CONCLUSION: Men started b/tsDMARD earlier than women, particularly regarding disease duration and disease activity (DAS28), and had higher odds of reaching remission. This highlights the importance of early initiation of second line treatments, and suggests to target an earlier stage of disease in women to match the benefits observed in men.
Authors: Damini Jawaheer; Paul Maranian; Grace Park; Maureen Lahiff; Sogol S Amjadi; Harold E Paulus Journal: J Rheumatol Date: 2010-10-01 Impact factor: 4.666
Authors: Carson Maynard; Ted R Mikuls; Grant W Cannon; Bryant R England; Philip G Conaghan; Mikkel Østergaard; Daniel G Baker; Gail Kerr; Michael D George; Jennifer L Barton; Joshua F Baker Journal: Arthritis Care Res (Hoboken) Date: 2020-03 Impact factor: 4.794
Authors: Moetaza M Soliman; Kimme L Hyrich; Mark Lunt; Kath D Watson; Deborah P M Symmons; Darren M Ashcroft Journal: J Rheumatol Date: 2011-12-15 Impact factor: 4.666
Authors: Marion Couderc; Jacques-Eric Gottenberg; Xavier Mariette; Bruno Pereira; Thomas Bardin; Alain Cantagrel; Bernard Combe; Maxime Dougados; René-Marc Flipo; Xavier Le Loët; Thierry Shaeverbeke; Philippe Ravaud; Martin Soubrier Journal: Rheumatology (Oxford) Date: 2014-05-11 Impact factor: 7.580